Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis

Clinics in Liver Disease

Volumn 4, Issue 1, 2000, Pages 97-113

  Sherlock, Sheila ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORAMBUCIL; COLESTYRAMINE; CORTICOSTEROID; CORTISONE; CYCLOSPORIN A; ESTROGEN; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NALMEFENE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OPIATE ANTAGONIST; PENICILLAMINE; PREDNISOLONE; URSODEOXYCHOLIC ACID; VITAMIN D;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE CHOLANGITIS; AUTOIMMUNE DISEASE; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; CHILD; CHOLANGITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; INFECTION; LIVER DISEASE; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOMALACIA; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PRURITUS; REVIEW;

EID: 0034425045     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(05)70098-2     Document Type: Article

References (109)

1. Primary sclerosing cholangitis: A long term follow-up study
2. Primary biliary cirrhosis
3. Histological evidence for recurrence or primary biliary cirrhosis after liver transplantation
4. Autoimmune cholangiopathy: Part of the spectrum of autoimmune chronic active hepatitis
5. The pruritus of cholestasis: Potential pathogenic and therapeutic implications of opioids
6. Open-label trial of oral Nalmefene for the pruritus of cholestasis
7. Hepatobiliary disease in ulcerative colitis. An analysis of 18 patients with hepatobiliary lesions classified small-duct primary sclerosing cholangitis
8. Elevated circulating immune complexes in primary sclerosing cholangitis
9. Prevalence and pattern of familial disease in primary biliary cirrhosis
10. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential
11. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis
12. Biliary tract carcinoma complicating primary sclerosing cholangitis: Evaluation with CT, cholangiography, US and MR imaging
13. Effect of procto-colectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis
14. Fatigue in primary biliary cirrhosis
15. Primary sclerosing cholangitis - A review of its clinical features, cholangiography and hepatic histology
16. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy
17. Primary biliary cirrhosis associated with mixed type autoimmune hemolytic anemia and sicca syndrome: A case report and review of literature
18. Prognosis in primary biliary cirrhosis: Model for decision making
19. Primary sclerosing cholangitis refinement and validation of survival models
20. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis
21. MR cholangiography in primary sclerosing cholangitis
22. Primary sclerosing cholangitis: Liver transplantation or biliary surgery
23. Natural history and prognostic variables in primary sclerosing cholangitis
24. Mitochondrial and other tissue antibodies in relatives of patients with biliary cirrhosis
25. Antimitochondrial antibodies in primary biliary cirrhosis recognize both specific peptides and shared epitopes of the M2 family of antigens
26. High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis
27. Autoimmune cholangitis in a patient with celiac disease: A case report and review of the literature
28. Autoimmune cholangitis: A variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases
29. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: Preliminary results after 2 years
30. Neutrophil cytoplasmic autoantibodies after liver transplantation in patients with primary sclerosing cholangitis
31. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: Predominance of the Th1 subset
32. Fibrous and obliterative cholangitis in liver allografts: Evidence of recurrent primary sclerosing cholangitis
33. Low-dose methotrexate in primary biliary cirrhosis. Long-term results of a placebo-controlled trial
34. Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis
35. Ulcerative colitis in chronic liver disease
36. Relation between Escherichia coli R (rough) forms in gut, and in liver, and primary biliary cirrhosis
37. Three-dimensional structure of the major autoantigen in primary biliary cirrhosis
38. Endoscopic needle aspiration biopsy at ERCP in the diagnosis of biliary strictures
39. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes
40. Distribution of pyruvate dehydrogenase dihydrolipoamide acetyltransferase (PDC-E2) and another mitochondrial marker in salivary gland and biliary eipthelium from patients with primary biliary cirrhosis
41. Toward better treatment of primary sclerosing cholangitis
42. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography
43. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?
44. Optimal timing of liver transplantation for primary biliary cirrhosis
45. The association between primary biliary cirrhosis and coeliac disease: A study of relevant prevalences
46. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits
47. A prospective study of biliary cytology in 100 patients with bile duct strictures
48. Primary sclerosing cholangitis
49. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis
50. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth
51. Ursodiol for primary sclerosing cholangitis
52. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
53. Advances in primary sclerosing cholangitis
54. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation
55. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis
56. Presentation and course of asymptomatic primary biliary cirrhosis
57. Primary sclerosing cholangitis: Findings on cholangiography and pancreatography
58. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium
59. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis
60. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders
61. Three patients with autoimmune cholangiopathy treated with prednisolone
62. HLR DR4 is a marker for rapid disease progression in primary sclerosing cholangitis
63. Natural history of primary biliary cirrhosis
64. Antimitochondrial antibody negative primary biliary cirrhosis. A distinct syndrome of autoimmune cholangitis
65. Reticulo-endothelial system Fc receptormediated clearance of IgG tagged erythrocytes from the circulation of patients with idiopathic ulcerative colitis and chronic liver disease
66. Pericholangitis and ulcerative colitis. Pathology, etiology and pathogenesis
67. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis
68. Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation
69. PBC and AMA - What is the connection?
70. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis
71. Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis
72. Chronic active hepatitis with histological features of primary biliary cirrhosis
73. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis
74. Long-term treatment of primary biliary cirrhosis with ursodeoxycholic acid: Results of a randomized, double-blind, placebo-controlled trial
75. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis
76. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease
77. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
78. Ursodiol for the long-term treatment of primary biliary cirrhosis
79. CT appearance of sclerosing cholangitis
80. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease
81. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease
82. Bones and primary biliary cirrhosis
83. Primary biliary cirrhosis Chronic non-suppurative destructive cholangitis
84. Expression of pyruvate-dehydrogenase complex PDC-E-2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis
85. Primary biliary cirrhosis
86. Risk factors in primary sclerosing cholangitis
87. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis
88. Serum bilirubin: A prognostic factor in primary biliary cirrhosis
89. Autoimmune cholangitis: A unique entity?
90. Overview of chronic cholestatic conditions in adults. Terminology and definitions
91. Therapeutic trials in primary biliary cirrhosis
92. Primary biliary cirrhosis
93. Are antimitochondrial antibodies in primary biliary cirrhosis induced by R (rough) mutants of enterobacteriacea?
94. Hepatobiliary disease that precedes ulcerative colitis
95. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis
96. Genomic associations in AMA-positive and AMA-negative primary biliary cirrhosis
97. Chronic cholestasis in rats induces amhedonia and loss of social interest
98. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins
99. Liver transplantation for primary biliary cirrhosis
100. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis
101. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: Results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses
102. Mycobacterium Gordonae DNA in liver tissue of patients with primary biliary cirrhosis
103. Serological tests in diagnosis of primary biliary cirrhosis
104. Detection of retroviral antibodies in primary biliary cirrhosis
105. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis
106. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis
107. Intestinal lung disease in primary biliary cirrhosis
108. Primary sclerosing cholangitis
109. Primary sclerosing cholangitis in 32 children: Clinical, laboratory, and radiographic features